公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) | Schuler M; CHIH-HSIN YANG ; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L. | Journal of Thoracic Oncology | 2 | 1 | |
2016 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial | Schuler M; CHIH-HSIN YANG ; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators | Annals of Oncology | 118 | 110 | |
2015 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials | CHIH-HSIN YANG ; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. | The Lancet Oncology | 1318 | 1236 | |
2012 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial | Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG | The Lancet Oncology | 879 | 785 | |
2022 | Chiral thermally activated delayed fluorescence emitters for circularly polarized luminescence and efficient deep blue OLEDs | Huang Z; Huang C.-W; Tang Y.-K; Xiao Z; Li N; Hua T; Cao X; Zhou C; Wu C.-C; Yang C.; CHUNG-CHIH WU | Dyes and Pigments | 8 | 7 | |
2018 | Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) | Wu Y.-L; Hirsh V; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Schuler M; Mok T; Yamamoto N; O’Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG | Patient | 20 | 17 | |
2016 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials | CHIH-HSIN YANG ; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu Y.-L. | Annals of Oncology | 152 | 142 | |
2019 | First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials | Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG | Lung Cancer | 26 | 19 | |
2022 | High-efficiency and low roll-off deep-blue OLEDs enabled by thermally activated delayed fluorescence emitter with preferred horizontal dipole orientation | Hua T; Liu Y.-C; Huang C.-W; Li N; Zhou C; Huang Z; Cao X; Wu C.-C; Yang C.; CHUNG-CHIH WU | Chemical Engineering Journal | 20 | 20 | |
2015 | Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis | Lee C.K; Wu Y.-L; Ding P.N; Lord S.J; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla R.J; CHIH-HSIN YANG | Journal of Clinical Oncology | 277 | 244 | |
2021 | A multi-year short-range hindcast experiment with CESM1 for evaluating climate model moist processes from diurnal to interannual timescales | Ma H.-Y; Zhou C; Zhang Y; Klein S.A; Zelinka M.D; Zheng X; Xie S; Chen W.-T; CHIEN-MING WU ; WEI-TING CHEN | Geoscientific Model Development | 8 | 7 | |
2017 | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC | Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit E.F; Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG ; Zhou C; Vokes E. | Journal of Thoracic Oncology | 184 | 168 | |
2019 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer | Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG ; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. | Lung Cancer | 26 | 26 |